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Pathologic angiogenesis is intrinsically associated with the
ﬁbrogenic progression of chronic liver diseases. Hypoxia,
hypoxia-inducible factors, and other signals and mediators
released by various cells of the liver drive and modulate the
critical proﬁbrogenic and proangiogenic role of hepatic
myoﬁbroblasts.
Pathologic angiogenesis appears to be intrinsically asso-
ciated with the ﬁbrogenic progression of chronic liver
diseases, which eventually leads to the development of
cirrhosis and related complications, including hepatocel-
lular carcinoma. Several laboratories have suggested that
this association is relevant for chronic liver disease pro-
gression, with angiogenesis proposed to sustain ﬁbro-
genesis. This minireview offers a synthesis of relevant
ﬁndings and opinions that have emerged in the last few
years relating liver angiogenesis to ﬁbrogenesis. We
discuss liver angiogenesis in normal and pathophysiologic
conditions with a focus on the role of hypoxia and hypoxia-
inducible factors and assess the evidence supporting a
clear relationship between angiogenesis and ﬁbrogenesis.
A section is dedicated to the critical interactions between
liver sinusoidal endothelial cells and either quiescent
hepatic stellate cells or myoﬁbroblast-like stellate cells.
Finally, we introduce the unusual, dual (proﬁbrogenic and
proangiogenic) role of hepatic myoﬁbroblasts and
emerging evidence supporting a role for speciﬁc mediators
like vasohibin and microparticles and microvesicles. (Cell
Mol Gastroenterol Hepatol 2015;1:477–488; http://
dx.doi.org/10.1016/j.jcmgh.2015.06.011)
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Angiogenesis and Liver Fibrogenesis
Fibrogenic progression of chronic liver diseases (CLDs),
eventually leading to the development of liver cirrhosis and
related complications including hepatocellular carcinoma
(HCC), is intimately associated with pathologic angiogenesis
and sinusoidal remodeling.1–6 This is not surprising because
angiogenesis is amajor feature of anywound healing response
and chronic activation of wound healing is a general
mechanism involved in the progression of CLDs.7–10 Some
researchers, including the authors of this review, go
further2–4,9–15 in suggesting additionally that 1) hypoxia (the
most obvious stimulus for angiogenesis, commonly detectedin progressive CLDs1–6,16), hypoxia-inducible factors (HIFs),
and angiogenesis may have a major role in sustaining and
potentially driving liver ﬁbrogenesis; 2) hepatic myoﬁbro-
blasts (MFs), regardless of origin, are critical cells in governing
and modulating the interactions between inﬂammation,
angiogenesis, and ﬁbrogenesis; 3) liver angiogenesis has a role
in the genesis of portal hypertension and related complica-
tions in advanced stages of CLDs; and 4) microparticles/
microvesicles released by either fat-laden hepatocytes or
portal MFs have an emerging role in mediating angiogenesis
and vascular remodeling. This review offers a synthesis of the
most relevant recent data and opinions regarding the close
relationship between liver angiogenesis and ﬁbrogenesis.
Established concepts about mechanisms of liver angiogenesis,
liver ﬁbrogenesis, and CLD progression will not be addressed.
Moreover, in this review, the relationship between angiogen-
esis and portal hypertension and related complications are not
discussed; readers interested in this speciﬁc topic should refer
to a recent authoritative review.13Angiogenesis in the Liver: General
Considerations
Liver angiogenesis occurs in both physiologic (ie, liver
regeneration) and pathologic conditions, including ischemia,
progressive CLDs, hepatocellular carcinoma, and metastatic
liver cancer.1–5 Angiogenesis in the liver is similar to
angiogenesis in other tissues and organs; however, as sug-
gested by several groups,1–5,10–12 pathologic angiogenesis
occurring during the progression of CLDs can be signiﬁ-
cantly affected by liver-speciﬁc events, interactions between
different hepatic cell populations, and the involvement of
atypical proangiogenic mediators.
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predominates in a speciﬁc CLD is relevant to angiogenesis.
Although pathologic liver angiogenesis has been described
in all CLDs irrespective of etiology, it is much more promi-
nent under conditions of bridging or postnecrotic ﬁbrosis
(eg, in chronic viral infection or, to a lesser extent, in
autoimmune diseases) than in conditions characterized by
pericellular or perisinusoidal ﬁbrosis (as in non-alcoholic
fatty liver disease or alcoholic liver disease) or by biliary
ﬁbrosis.3,9,10 This suggests an inverse correlation between
angiogenesis and the potential for ﬁbrosis reversibility,
which is more evident in conditions characterized by peri-
cellular or perisinusoidal ﬁbrosis and biliary ﬁbrosis than in
those associated with bridging ﬁbrosis.9 This may be related
to the unique tissue localization, phenotypic proﬁle, and
functional role of hepatic stellate cells (HSCs).
HSCs, which in physiologic conditions synthesize extra-
cellular matrix components in the space of Disse, store
retinoids and possibly contract in response to vasoactive
mediators to modulate sinusoidal blood ﬂux, are also liver-
speciﬁc pericytes. During the progression of CLDs, HSCs are
the most relevant myoﬁbroblast precursors and proﬁbro-
genic hepatic cells.2,17–21 HSCs, particularly in their
activated and MF-like phenotype (HSC/MFs), modulate
angiogenesis in a way that, as we will describe, relates to the
role attributed to them as microcapillary pericytes. Hepatic
MFs, a heterogenous population of proﬁbrogenic, highly
proliferative, and contractile cells, can also originate from
portal MFs and bone marrow-derived stem cells recruited
into the injured liver, and these may also play a role in
angiogenesis.17–22
The relevance of intense cross-talk between hepatic cell
populations in pathologic angiogenesis is strongly sup-
ported by the knowledge that major proangiogenic media-
tors such as vascular endothelial growth factor (VEGF) and
platelet-derived growth factor (PDGF), are produced and
released by several liver cell types involved in CLD
progression, including hypoxic hepatocytes and hypoxia-
responsive macrophages and MFs.1–3,9–12 The role of
liver-speciﬁc proangiogenic mediators such as angiopoietin-
like-3 peptide (ANGPTL3)23 is controversial. ANGPTL3,
which belongs to a family of mediators described as playing
major roles in the trafﬁcking and metabolism of lipids, was
reported to induce haptotactic endothelial cell adhesion and
migration, possibly by binding to avb3 integrin.
23 However,
no further studies have been published on the role of this
mediator in either physiologic or pathologic liver angio-
genesis. As we will discuss, a more interesting role is
attributed to the antiangiogenic protein vasohibin, which
may have a dual role in inhibiting not only angiogenesis but
also ﬁbrogenesis, likely by deactivating HSCs.24
Hypoxia, Pathologic Angiogenesis, and
Liver Fibrogenesis: Interconnected
Events
Angiogenesis is best deﬁned as a dynamic, hypoxia-
stimulated, and growth factor-dependent process leading
to the formation of new blood vessels from preexistingones.25,26 Hypoxia and HIFs are critical in sustaining the
ﬁbrogenic progression of CLDs, representing a persistent
driving force able to directly affect the behavior of hepatic
cell populations, including proﬁbrogenic and proangiogenic
MFs.1–5,10–13,16
Detection of hypoxic areas is a common ﬁnding at any
stage of CLD, increasing progressively from early injury to
the development of cirrhosis, with hypoxia and HIFs serving
throughout as proangiogenic stimuli in the overall, etiology-
independent scenario of chronic wound healing. CLD pro-
gression itself is a major contributor to hypoxia due to the
formation of regenerative nodules of parenchyma sur-
rounded by evolving ﬁbrotic septa and vascular remodeling
that, along with progressive capillarization of the sinusoids,
leads to an impairment of oxygen diffusion. A vicious circle
between ﬁbrosis and pathologic angiogenesis is likely to
occur10,12,27 in which parenchymal hypoxia, through the
action of HIFs, up-regulates expression of wound healing-
related factors and mediators that should facilitate liver
repair and revascularization. However, pathologic angio-
genesis can be inefﬁcient due to the immaturity and
permeability of VEGF-induced neovessels and, as a result,
may be unable to correct liver hypoxia. Pathologic angio-
genesis and hypoxia may act synergistically in disrupting
normal tissue repair, thereby promoting the development of
liver ﬁbrosis.27
The connection between pathologic angiogenesis and
ﬁbrogenesis in progressive CLDs is strongly suggested by
their parallel development in all major human forms of CLD
and animal models of CLDs, with several laboratories
describing high numbers of endothelial cells and micro-
vascular structures within ﬁbrotic septae and in expanded
portal areas.1–5,10–13,16,28–30 The response to hypoxia and
VEGF (the major proangiogenic target gene) expression can
be seen in liver sinusoidal endothelial cells (LSECs) and in
hepatocytes1,3,4,10,28 and HSC/MFs of developing septa and
at the borders of more mature and larger ﬁbrotic septa.29,30
Studies performed in HIF-1a liver conditional knockout
mice provided the ﬁrst deﬁnitive in vivo evidence for
hypoxia-dependent induction of ﬁbrogenesis.31 However,
the most convincing evidence relating angiogenesis and
ﬁbrogenesis came through in vivo studies indicating that
experimental antiangiogenic therapy was highly effective in
signiﬁcantly reducing ﬁbrogenic progression. As summa-
rized in Table 1, whatever the speciﬁc molecule or tool
employed, experimental antiangiogenic therapy always
resulted in a signiﬁcant reduction not only of angiogenesis
but also of the inﬂammatory inﬁltrate, the number of
a-smooth muscle actin (a-SMA)-positive MFs and the
extent of ﬁbrosis.32–42 In some studies, experimental anti-
angiogenic therapy also resulted in a signiﬁcant reduction of
portal pressure and collateral vessel formation, as reported
with sorafenib in cirrhotic animals34,43 and with different
molecules and tools in portal hypertensive animals.9,24,44–49
To our knowledge, only two studies have been published
that represent exceptions to this general ﬁnding. The ﬁrst
one was published in 2009 by Patsenker et al,50 who re-
ported that pharmacologic inhibition of integrin anb3 by
cilengitide, although able to suppress liver angiogenesis,
Table 1.Published Studies Examining Antiangiogenic Therapy in Rodent Models of Chronic Liver Disease
Antiangiogenic Molecule Mode of Action Major Findings References
Sunitinib (SU11248) Inhibition of multitargeted receptor
tyrosine kinase
Decrease in hepatic vascular density,
inﬂammatory inﬁltrate, a-SMA
abundance, collagen expression, and
portal pressure in cirrhotic rats
32
Sorafenib Inhibition of VEGF-R2, PDGF-Rb
and RAF/MEK/ERK pathway
Decrease in splanchnic neovascularization,
hyperdynamic splanchnic and systemic
circulations, extent of portosystemic
collaterals, portal pressure; improvement
in liver damage and intrahepatic ﬁbrosis,
inﬂammation, and angiogenesis in
cirrhotic rats
34,43
Neutralizing monoclonal
antibodies for VEGF-R2
Neutralization of VEGF-R2 Reduction in ﬁbrosis and suppression of
hepatic neovascularization
35
Neutralizing monoclonal
antibodies for PlGF
Neutralization of PIGF Reduction in angiogenesis, arteriogenesis,
inﬂammation, ﬁbrosis, and portal
hypertension in cirrhotic mice
36
Adenovirus expressing
soluble Tie2 (AdsTie2)
Binds angiopoietin 1 and blocks
angiopoietin signaling
Inhibition of liver ﬁbrosis both induced by
CCl4 and BDL in mice; reduction in
collagen and number of activated
myoﬁbroblasts
37
Cxcl9 Reduction in VEGF-R2,
phospholipase Cg and ERK
phosphorylation
Inhibition of proliferation and migration of
VEGF-stimulated endothelial cells and
stellate cells; attenuation of
neoangiogenesis and experimental liver
ﬁbrosis in mice
38
Cannabinoid receptor 2
agonist
Stimulation of cannabinoid
signalling
Improvement of portal hypertension,
portosystemic collaterals, and
mesenteric and intrahepatic
angiogenesis as well as ﬁbrosis in
cirrhotic rats
39
AM1241 and F13A Stimulation of CB2 receptor
(AM1241) and apelin receptor
blockade (F13A)
Reduction in ﬁbrosis, improvement of portal
pressure, improved cell viability,
reduction in angiogenesis and cell
inﬁltration in cirrhotic rats
40
Largazole Inhibition of histone deacetylase Inhibition of HSCs activation, TGF-b and
VEGF signaling and induction of HSCs
apoptosis; inhibition of ﬁbrosis,
angiogenesis, and inﬂammation in
cirrhotic mice
41
Rifaximin Inhibition of TLR4 dependent
ﬁbronectin-mediated cross-talk
between HSCs and endothelial
cells
Decrease in portal pressure, ﬁbrosis,
angiogenesis and ﬁbronectin deposition
in BDL mice
42
Monoclonal antibody
against VEGF-R2 and
inhibitor of VEGF-R2
autophosphorylation
Neutralization of VEGF-R2 or block
of VEGF-R2 phosphorylation
Inhibition in the formation of portal-systemic
collateral vessels in partial portal vein-
ligated mice and rats
44
SU5416 Inhibition of VEGF-R2 Decrease in hyperdynamic splanchnic
circulation, and portal-systemic collateral
vessels in portal hypertensive rats
45
Rapamycin and Gleevec VEGF signaling inhibition
(rapamycin), PDGF signaling
inhibition (Gleevec)
Reduction in splanchnic neovascularization
and pericyte coverage of neovessels;
decrease in portal pressure and
portosystemic collateralization in portal
vein-ligated rats
46
Octreotide Inhibition of cell proliferation and
neovascularization
Decrease in splanchnic neovascularization,
VEGF expression at early stages, but not
in advanced stages, of portal
hypertension in cirrhotic rats
47
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Table 1.Continued
Antiangiogenic Molecule Mode of Action Major Findings References
F13A APJ receptor blockade (F13A or
apelin receptor antagonist)
Decrease in splanchnic neovascularization,
expression of the proangiogenic factors
VEGF, PDGF, and ang-2, reduction in
formation of portosystemic collateral
vessels in portal hypertensive rats
48
Pigment epithelium-derived
factor (PEDF)
Cleavage of VEGF-R1
transmembrane domain,
interference with VEGF signaling
Attenuation of portal hypertension-
associated pathological
neovascularization; decrease in liver
ﬁbrosis, portosystemic collateralization
and portal pressure in BDL rats
49
Vasohibin (VASH) Reversal of VASH-induced negative
feedback loop of VEGF
angiogenesis
VASH overexpression results in reduction of
pathologic angiogenesis, attenuation of
liver ﬁbrosis, decreases in
portocollateralization, splanchnic blood
ﬂow, portohepatic resistance, and portal
pressure
24
Note: AM1241, (2-iodo-5-nitrophenyl)-[1-[(1-methylpiperidin-2-yl)methyl]indol-3-yl]methanone; BDL, bile duct ligation; CB2,
cannabinoid type 2 receptor; CCl4, carbon tetrachloride; Cxcl9 chemokine (C-X-C motif) ligand 9; F13A, Gln-Arg-Pro-Arg-Leu-
Ser-His-Lys-Gly-Pro-Met-Pro-Ala; HSCs, hepatic stellate cells; PDGF, platelet-derived growth factor; PIGF, placental growth
factor; RAF/MEK/ERK, Raf/mitogen-activated protein (MAP) kinase kinase/extracellular signal-regulated kinase; a-SMA,
a-smooth muscle actin; SU5416, semaxanib; TGF-b, transforming growth factor-b; TLR4, Toll-like receptor 4; VASH, vaso-
hibin; VEGF, vascular endothelial growth factor; VEGF-R2, vascular endothelial growth factor receptor type 2.
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experimental and clinical study suggested that the devel-
opment of liver ﬁbrosis was associated with decreased
expression of VEGF and sinusoidal rareﬁcation of the
ﬁbrotic scar.51 These investigators reported that experi-
mental resolution of ﬁbrosis was accompanied by an in-
crease in hepatic VEGF levels and revascularization of
ﬁbrotic septa, events that were prevented by ablating VEGF
in myeloid cells or through pharmacologic inhibition of
vascular endothelial growth factor receptor type 2 (VEGF-
R2) signaling.
The question of whether available antiangiogenic drugs
might be useful in treating patients with cirrhosis and portal
hypertension remains unanswered, with some positive data
reported in cirrhotic patients with HCC;52 however, several
signiﬁcant concerns were raised53 related to the known
severe side effects of these drugs (eg, sorafenib) as well
as the increased risk of bleeding reported in cirrhotic pa-
tients with HCC.54 On the other hand, although VEGF is
unequivocally a critical proﬁbrogenic mediator and has a
well-established role in endothelial cell survival and prolif-
eration, it may have also a role in ﬁbrosis resolution.55
While blocking the interaction between VEGF and VEGF-
R2 does not result (as hypothesized) in an improvement
or acceleration of ﬁbrosis resolution, the availability of VEGF
is critical in chemokine (C-X-C motif) ligand 9 (CXCL9)- and
matrix metalloprotease 13 (MMP13)-dependent ﬁbrosis
resolution in different murine models of ﬁbrosis. This
apparent paradox is explained by the fact that blocking
VEGF-R2 effectively blocks VEGF-dependent recruitment of
mononuclear cells and changes in vascular permeability.
Blocking VEGF-R2 thereby potentially reduces the recruit-
ment of “resolution” macrophages, which have an importantrole in ﬁbrosis reversal. Indeed, in that study, the degree of
impairment of ﬁbrosis resolution obtained by blocking
VEGF-R2 was nearly identical to that seen with macrophage
depletion.55
Macrophages and Inﬂammation in
Relation to Angiogenesis
Chronic liver inﬂammation is a key requirement for the
progression of liver ﬁbrosis, but there is little known about
its role in promoting ﬁbrosis-associated angiogenesis.
Although inﬂammation-associated angiogenesis may
contribute to both initiation of CLDs and their progression
toward cirrhosis and HCC, the available data refer primarily
to HCC and to macrophages in the tumor micro-
environment.56–59 Studies performed using specimens from
CLD patients and from mouse models have shown that
chemokine-dependent accumulation of monocyte-derived
macrophages represents a relevant mechanism for perpet-
uating hepatic inﬂammation and promoting ﬁbrogenesis.60
In particular, the chemokine receptor 2 (CCR2) and its
ligand CCL2 have a key role in promoting the accumulation
of certain monocyte subsets in the liver, in particular Ly6Cþ
(Gr1þ) monocytes. Macrophages derived from these mono-
cytes release proinﬂammatory cytokines and can directly
activate proﬁbrogenic hepatic MFs.60
Accordingly, CCL2-dependent inﬁltrating macrophages
are critical in sustaining angiogenesis in experimental
models of CLDs. A study has shown that these cells promote
angiogenic vessel sprouting, particularly in the portal vein
system, by releasing VEGF-A and other potential proangio-
genic factors such as matrix metalloprotease 9 (MMP9).61
This study convincingly demonstrated that angiogenesis is
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hepatic neovascularization correlates with ﬁbrosis stage.
Inﬁltrating and CCL2-dependent inﬂammatory cells mediate
induction of ﬁbrosis-associated pathologic angiogenesis,
and, accordingly, pharmacologic inhibition of CCL2 blocks
angiogenesis in experimental ﬁbrosis by inhibiting the
inﬁltration of CCL2-dependent monocyte/macrophages.61
Hepatic MFs in CLD Progression: The
Cells That Drive Both Angiogenesis
and Fibrogenesis
Hepatic MFs, particularly HSC/MFs, play a critical role in
CLD progression through their unique ability to act as
hypoxia-sensitive and cytokine- and chemokine-modulated
cellular mediators at the crossroads between chronic liver
injury, inﬂammation, pathologic angiogenesis, and
ﬁbrogenesis.1–5,10 MFs are critical target cells, able to inte-
grate signals from the microenvironment (including from
hypoxia, contact with altered extracellular matrix, and
plasma proteins) and from surrounding liver cells, acting as
both proﬁbrogenic and proangiogenic effector cells (see
Figure 1). We propose that the overall proangiogenic role of
MFs is the result of their interactions with surrounding
hepatic cells and their exposure to the altered hepatic
microenvironment during CLD progression. In the next
sections, we focus particularly on LSECs and the relevance
of the interactions between LSECs, HSC, and HSC/MFs,
as well as on both hypoxia-dependent and hypoxia-
independent responses of activated MFs.11
Liver Sinusoidal Endothelial Cells and Their
Interactions with Hepatic Stellate Cells or
Myoﬁbroblast-Like Cells From Activated Hepatic
Stellate Cells
Under physiologic conditions, the intrahepatic vascular
system is composed of different kinds of vessels, including
liver sinusoids, portal venules, hepatic arterioles, central
venules, and lymphatic vessels. These vessels are composed
of endothelial cells and smooth muscle cells as well as, for
liver sinusoids, HSCs, which act as liver speciﬁc pericytes.
All these cells, plus resident Kupffer cells and other blood-
derived cells, interact with each other. Signaling between
these cells maintains sinusoidal homeostasis and is signiﬁ-
cantly altered in pathophysiologic conditions.62
LSECs represent the majority of liver endothelial cells
and have a morphologic and functional phenotype that is
strikingly different from that of endothelial cells of other
vascular units in the liver and elsewhere. Fenestration and a
lack of a typical basement membrane are predominant
features of the LSEC phenotype but are lost in CLDs.62,63
Under physiologic conditions, quiescent HSCs, which
reside in the space of Disse and interact through their
multiple processes with hepatocytes and LSECs, con-
tribute to vitamin A and retinoid metabolism as well as to
deposition and remodeling of the extracellular matrix in the
space of Disse.64 Quiescent HSCs, which also interact
with the axonal processes of autonomic nerve ﬁbers, areliver-speciﬁc pericytes,65 able to respond to a variety of
vasoactive mediators and may regulate sinusoidal blood
ﬂow through their perisinusoidal processes.62–66
The literature suggests that human HSCs contract mainly
in response to endothelin-1 (ET-1), thrombin, and
angiotensin-II, and relax in response to nitric oxide (NO)
and NO donors, prostaglandin E2, somatostatin, and adre-
nomedullin.64,65 There is considerable support for the
paradigm that under conditions of chronic liver injury two
features predominate: 1) overproduction of ET-1 by acti-
vated HSCs; and 2) a signiﬁcant reduction in NO release by
LSECs.62–65
HSCs, which are a major source of ET-1, also represent a
target for this vasoactive molecule during liver injury, with
ET-1 (either from LSECs or activated HSCs, acting in a
paracrine or autocrine way) exerting a prominent contrac-
tile effect on HSCs and MFs, and likely contributing to portal
hypertension in the cirrhotic liver67–69 as well as having a
growth inhibitory effect on HSC/MFs.70 During CLD pro-
gression, this results in an imbalance in vasoactive media-
tors and leads to abnormal sinusoids, with remodeling and
constriction of the intrahepatic sinusoidal vasculature and a
resulting increase in hepatic vascular resistance early in
intrahepatic portal hypertension.62 As highlighted by Iwa-
kiri et al,62 this differs from events in the mesenteric
vascular bed, which are characterized by vasodilation and
reduced resistance from up-regulation of vasodilators such
as NO; this in turn leads to increased ﬂow to the portal vein.
The combined result of changes in the intrahepatic and
mesenteric vasculature is an increase in intrahepatic
resistance and portal blood ﬂow from the splanchnic cir-
culation, leading to increased portal pressure and portal
hypertension.
Regulation of the phenotype of LSECs can be viewed as
the net result of the action of different signals that include
soluble factors (mainly VEGF, angiopoietins, ephrins, and
ﬁbroblast growth factors) and mechanical forces such as
those due to shear stress. These signals are critical in
modulating endothelial NO synthase (eNOS) activity in
LSECs, resulting in the regulation of ﬂow and vascular tone
in the liver sinusoids.62,71 LSECs release in a paracrine way
several mediators that are involved in maintaining a
“physiological” LSEC phenotype but also affect the early
response of HSCs. For example, LSECs can produce the
cellular isoform of ﬁbronectin in response to injury; ﬁbro-
nectin has been reported to stimulate HSC synthesis of
ET-1.72 ET-1, in turn, may differentially affect proliferation
of HSCs, promoting proliferation in transiently activated
HSCs but inhibiting it in fully activated HSCs.70,73
During CLD progression, LSEC phenotype changes
dramatically during the so-called capillarization of sinusoids
in association with a reduction in eNOS activity and NO
synthesis.62 This is possibly due to extensive post-
translational dysregulation of eNOS as a consequence of
changes in phosphorylation or interactions with proteins
such as calmodulin, caveolin-1, and protein kinase B
(Akt).74,75 The reduction in NO release by LSECs is believed
to have a more direct role in sustaining ﬁbrogenesis because
NO contributes to the maintenance of quiescence of HSCs
Figure 1. Schematic representation of the critical role of activated myoﬁbroblasts (MFs) in the scenario of a pro-
gressive chronic liver disease with the direct response to hypoxic conditions and the response to mediators released
by other hepatic cell populations (under hypoxia or after chronic injury) or available in the microenvironment and being
able to sustain both proangiogenic and proﬁbrogenic role of MFs. Chronic conditions of injury as well as hypoxic
conditions operate as efﬁcient events/stimuli able to up-regulate transcription and release of critical proangiogenic mediators
(with some also able to sustain ﬁbrogenesis) by hepatocytes, endothelial cells, macrophages, or activated MFs (the latter cells
being stimulated to produce proangiogenic cytokines also by leptin). Endogenous vasohibin 1 production is regulated by
VEGF in a spatially and temporally coordinated way that operates a negative-feedback loop, driving pathologic angiogenesis
through an overall positive effect on activation of HSCs and ﬁbrogenic progression. However, it has been suggested that
ectopic overexpression of this antiangiogenic protein (resulting in inhibition of ﬁbrogenesis), being not regulated by VEGF, can
disrupt the negative-feedback loop, thus generating constant but lower levels of VEGF synthesis, which are believed to be
sufﬁcient to maintain vascular homeostasis but not to sustain pathologic angiogenesis. Green and red arrows in the ﬁgure
indicate stimulating or inhibitory effects, respectively.
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activated HSCs, with reduced levels of NO facilitating HSC
activation.76,77 The scenario may be even more complex
because HSCs can produce NO after injury,78 possibly in
response to up-regulation of inducible NOS activity induced
by proinﬂammatory cytokines or endotoxemia.62
LSECs produce mediators and factors that regulate both
regeneration and ﬁbrosis. LSECs, through interactions be-
tween VEGF and VEGF-R2, can release Wnt2 and hepatocyte
growth factor, which sustain proliferation of hepatocytes;79
moreover, a signiﬁcant amount of hepatocyte growth factor
is also released by bone marrow-derived LSEC progenitor
cells.80 LSECs from the livers of mice with biliary ﬁbrosis
have been reported to release proﬁbrogenic mediators such
as transforming growth factor b, bone morphogenetic pro-
tein 2, and PDGF-C and to decrease the release of putative
antiﬁbrotic factors such as follistatin and apelin.81Hypoxia-Dependent Proangiogenic Response
of Myoﬁbroblasts
Increased expression of VEGF in specimens from ﬁbrotic
or cirrhotic patients colocalizes with areas of hypoxia and is
mostly limited to hepatocytes and MFs.28–30 MFs respond to
hypoxic conditions through HIF-1a-dependent up-
regulation of VEGF and angiopoietin-1 (Ang-1) and of their
respective receptors VEGF-R2 and Tie2.29,80–85 Exposure of
HSC/MF to hypoxic conditions also results in HIF-1a-
dependent up-regulation of CCR1, CCR5, macrophage
migration inhibitory factor, interleukin-13 receptor-a1,
prolyl-4-hydroxylase-a2, and (in part) placental growth
factor, and HIF-1a-independent increased expression of
angiopoietin-like 4 and prolyl-4-hydroxylase-a1.85 MFs can
also directly respond to VEGF and Ang-1, with VEGF re-
ported to elicit increased proliferation as well as increased
synthesis of extracellular matrix components,28 and both
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HSC/MFs and MF-like cells from bone marrow-derived
mesenchymal stem cells.30,86,87
Hypoxia alone is able to induce oriented migration of
either HSC/MFs or MF-like cells by eliciting a biphasic
mechanism involving 1) an early phase of migration,
switched on by mitochondria-released reactive oxygen
species (ROS) and requiring redox-dependent activation of
extracellular-signal-regulated kinase and c-Jun-NH2-termi-
nal kinase isoforms; and 2) a delayed and sustained phase of
migration requiring the HIF-1a-mediated, ROS-stabilized
increased synthesis and release of VEGF.29,30,86,87 Overall
these data ﬁt well with morphologic evidence from both
experimental rodent models of ﬁbrosis and specimens from
hepatitis C virus cirrhotic patients.29,30
Positive staining for both HIF-2a and heme oxygenase-1
has been reported in a-SMA positive MFs in developing
septa and at the border of more mature and larger ﬁbrotic
septa.30 This scenario is similar to the previously described
ﬁnding that expression of VEGF, Ang-1, and related re-
ceptors VEGF-R2 and Tie229 was found at the leading edge
of tiny and incomplete developing septa, but not in larger
bridging septa. This suggests that pathologic angiogenesis
during the ﬁbrogenic progression of CLDs proceeds through
two different phases: 1) an early phase, occurring in
developing septa, in which ﬁbrogenesis and angiogenesis
are driven or modulated by HSC/MFs and by hypoxia itself;
and 2) a later phase, occurring in larger and more mature
ﬁbrotic septa, where chronic wound healing is likely to be
less active and ﬁbrogenic progression more established.
Morphologic analyses indicate that in the late setting
proangiogenic factors, particularly receptors like VEGF-R2
or Tie2, are expressed only by endothelial cells, a feature
that should favor stabilization of the newly formed
vessels.29
After exposure to hypoxia and proangiogenic mediators
released by other hepatic cells, including hepatocytes, MFs
may then migrate and align with the leading edge of
developing ﬁbrotic septa to drive at the same time ﬁbro-
genesis and pathologic angiogenesis, an attractive concept
that ﬁts well in the scenario of pathologic angiogenesis.88–90
Angiogenesis is controlled by the balance between proan-
giogenic mediators (eg, VEGF) and endogenous inhibitors of
angiogenesis. Pathologic angiogenesis can result from up-
regulation of angiogenic stimuli and concurrent down-
regulation of endogenous inhibitors, with a shift of the
balance in favor of proangiogenic stimuli.88–90 This general
view has been recently integrated, particularly for angio-
genesis in CLDs, by an elegant study investigating the role of
vasohibin.24
Vasohibin is a natural antiangiogenic protein that is
selectively induced in endothelial cells by VEGF and appears
to operate as an intrinsic, highly speciﬁc feedback inhibitor
of activated endothelial cells engaged in the process of
angiogenesis.91,92 Expression proﬁling of vasohibin-1 and its
relationship with VEGF expression, angiogenesis, and
ﬁbrogenesis in animal models of cirrhosis and portal hy-
pertension as well as in human cirrhotic liver specimens
showed that vasohibin-1 and VEGF are up-regulated inmesentery and liver in cirrhotic and precirrhotic portal
hypertensive rats and cirrhotic patients. This suggests that
vasohibin-1/VEGF cascades are spatially and temporally
coordinated through a negative-feedback loop driving
pathologic angiogenesis through an overall positive effect on
the activation of HSCs and ﬁbrogenic progression.24,92
Paradoxically, the overexpression of vasohibin-1 by
adenoviral gene transfer resulted in a signiﬁcant reduction
in pathologic angiogenesis, portal system collateralization,
splanchnic blood ﬂow, portohepatic resistance, and portal
pressure as well as an attenuation in liver ﬁbrogenesis that
was attributed, at least in part, to a vasohibin-1-mediated
inhibition of HSC activation.24,92 The investigators sug-
gested that ectopic overexpression of vasohibin-1, unlike
endogenous expression of the protein, is not regulated by
VEGF and therefore can disrupt the negative-feedback loop,
resulting in constant but lower levels of VEGF synthesis; this
is believed to be sufﬁcient to maintain vascular homeostasis
but not pathologic angiogenesis.24,92 Although several
questions remain unanswered,92 this study is extremely
promising particularly because overexpression of vasohibin-
1 appeared to affect pathologic angiogenesis without acting
on the normal liver vasculature.24Hypoxia-Independent Modulation of
Proangiogenic Role of Myoﬁbroblasts
Although hypoxia represents the most obvious proan-
giogenic environmental condition, the proangiogenic role of
MFs is regulated and modulated by a number of other me-
diators and events typical of conditions of chronic injury
and CLD progression, including growth factors, oncogenes,
cytokines, chemokines, metabolic or mitochondrial stress,
and ROS. Most if not all of these mediators, although theo-
retically hypoxia-independent, result in either increased
transcription of HIF-1a mRNA levels or (as described for
any condition leading to increased intracellular levels of
ROS) increased stabilization of HIF-1.
One example of a hypoxia-independent mediator is
apelin, the endogenous ligand of angiotensin-like-receptor 1
(APJ; AGTRL1). Apelin is signiﬁcantly increased in the serum
of cirrhotic patients and cirrhotic animals.93 Apelin and APJ
are expressed by MFs in cirrhotic animals and have been
also detected in the splanchnic vasculature of portal hy-
pertensive rats.48,93,94 Interestingly, apelin synthesis by
HSC/MFs is hypoxia-independent and up-regulated by
angiotensin II and ET-1; moreover, recombinant apelin can
directly stimulate collagen-I and PDGF receptor b (PDGF-
Rb) expression in MF-like cells.95 As a proof of principle,
experimental therapy based on the use of apelin receptor
antagonists resulted in a signiﬁcant reduction in liver
angiogenesis and ﬁbrosis as well as splanchnic angiogenesis
and portosystemic collateral vessel formation.40,48,93–95
Two other examples of hypoxia-independent mediators
are leptin and PDGF (particularly PDGF-BB). Leptin is an
adipocytokine that exerts a proﬁbrogenic effect during the
progression from nonalcoholic fatty liver disease (NAFLD)
to nonalcoholic steatohepatitis (NASH).7–12 In human HSC/
MFs, leptin up-regulates the expression of VEGF and Ang-1
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action of leptin on HSC/MFs is mediated through its binding
to its receptors (obesity receptor, ObR) and activation of
several signaling pathways, including extracellular-signal-
regulated kinase, Akt, and nuclear factor-kB, the latter
relevant to chemokine expression. Leptin also operates as a
proangiogenic mediator through the recruitment and sta-
bilization of HIF-1a and the nuclear translocation of HIF-
1.84 In vivo experiments conﬁrmed that the obesity recep-
tor colocalizes with VEGF and a-SMA after induction of
ﬁbrosis. The proangiogenic role of leptin in NAFLD and
NASH was also conﬁrmed by a study performed on Zucker
rats (animals carrying leptin receptor mutations) receiving
the steatogenic choline-deﬁcient and amino acid-deﬁned
diet.96
The role of PDGF (known to stimulate proliferation and
chemotaxis of MFs, particularly HSC/MFs) as a proangio-
genic mediator was ﬁrst described by Semela et al.97 PDGF
was reported to promote an “angiogenic” phenotype in HSCs
by modulating HSC-driven vascular tube formation in vitro
and enhanced coverage of sinusoids in vivo, with resulting
effects on vascular permeability and pressure regulation.
Proangiogenic signaling by PDGF required the involvement
of the multifunctional ephrin-B2 receptor tyrosine kinase.
PDGF and leptin have more recently been described as
playing a proangiogenic role in human HSC/MFs by sharing
a common signaling pathway that leads to up-regulation of
VEGF expression and release of the protein into the extra-
cellular medium.98 This common signaling pathway involves
activation of the mammalian target of rapamycin (mTOR)
pathway and generation of intracellular ROS by nicotin-
amide adenine dinucleotide phosphate (NADPH)-oxidase,
the latter event being relevant for increased HIF-1a stabi-
lization but not for the mammalian target of rapamycin
(mTOR) activation. Finally, another potential role for PDGF
was suggested by a study performed in myeloid cell-speciﬁc
HIF-1a or HIF-1b knockout mice subjected to bile duct
ligation, which suggested that a signiﬁcant amount of PDGF
produced in this experimental model was dependent on the
activation of HIFs in macrophages.99
Emerging Role of Microparticles
in Mediating Angiogenesis and
Vascular Remodeling
Microparticles (MPs) are small plasma membrane vesi-
cles surrounded by a phospholipid bilayer that are released
by apoptotic or stressed cells and usually contain proteins
derived from the parental cells. MP shedding is a highly
regulated process that occurs in several cell types. MPs have
been detected in various biological ﬂuids, including
peripheral blood and urine. In recent years, it has become
clear that MPs have important biological functions,
including the horizontal transfer of bioactive molecules such
as receptors, integrins, growth factors, RNAs, and micro-
RNAs.100,101 Circulating MPs are increased in animal models
of biliary cirrhosis and human cirrhosis and NASH, and at
least three different studies have linked the release of MPs
from hepatic cells to a proangiogenic effect in the setting ofCLD.102–105 Although the cells releasing these proangiogenic
MPs were different depending on the form of liver disease,
MPs released by damaged or activated cells contributed
signiﬁcantly to pathologic angiogenesis regardless of their
cell of origin.
One study provided evidence that cholangiocytes and
HSC/MFs can produce and then release (mainly in response
to PDGF) MPs containing Hedgehog (Hh) ligands. Hh ligands
activate Hh signaling in endothelial cells, causing signiﬁcant
effects in the bile duct ligation model of ﬁbrosis. This study
found that in the normal liver the low levels of Hh ligands
released by immature ductular-type progenitors are efﬁ-
ciently counteracted by the expression of Hh interacting
protein (HIP) expressed by either quiescent HSCs or
fenestrated LSECs. In conditions of chronic injury to biliary
structures, however, Hh interacting protein–expression is
repressed, and the activation of ductular-type progenitor
cells results in PDGF-BB up-regulation and release.
PDGF-BB, in turn, induces HSC/MFs and ductular cells to
produce and release Hh ligands in MPs; these promote
proliferation and survival of cholangiocytes and HSC/MFs as
well as induce changes in LSEC gene expression. Overall,
this results in capillarization of the sinusoids and the release
of vasoactive factors such as NO, contributing to vascular
remodeling in cirrhosis.103
A second study, focused on the role of MPs in NAFLD and
NASH, showed that hepatocytes exposed to conditions
mimicking the lipid accumulation and lipotoxicity that oc-
curs in the liver during forms of steatohepatitis can also
release MPs. These MPs from fat-laden hepatocytes were
found to act on endothelial cells and, after their internali-
zation, to promote pathologic angiogenesis as shown in vitro
and in vivo in mice exposed to a murine model of NAFLD/
NASH.105 The release of these MPs was caspase-3 depen-
dent. Of interest, large numbers of hepatocyte-derived MPs
were detected in the blood of mice with diet-induced
steatohepatitis, and MPs levels correlated with disease
severity. Genetic ablation of caspase-3 or RNA interference
directed against vanin-1 (expressed on MPs and mediating
contact with lipid rafts of endothelial cells) protected mice
from steatohepatitis-induced pathologic angiogenesis and
resulted in a loss of the proangiogenic effects of MPs by
reducing the extent of ﬁbrosis.
Finally, a third study suggested that portal MFs release
proangiogenic MPs that contribute to the vascular changes
leading to cirrhosis.15 Expression of collagen, type XV, a1
(COL15A1) by portal MFs was markedly increased in human
and rat liver tissue at advanced stages of ﬁbrosis caused by
either biliary or hepatocellular injury. In the cirrhotic liver,
COL15A1-expressing portal MFs were detected in an un-
usual perivascular distribution outlining vascular capillaries
proximal to reactive ductules, within large ﬁbrotic septa.
Portal MFs were found to release MPs containing VEGF-A;
this led to increased migration and tubulogenesis of LSECs
and human umbilical vein endothelial cells and was able to
trigger angiogenesis in matrigel plugs in mice. Chol-
angiocytes potentiated the angiogenic properties of portal
MFs by increasing VEGF-A expression and MP shedding.
This suggests that portal MFs have a signiﬁcant role in
September 2015 Angiogenesis and Liver Fibrogenesis 485angiogenesis and vascular remodeling, releasing VEGF-A
containing MP, acting as mural cells for newly formed ves-
sels, and driving angiogenesis and scar progression from
portal tracts into the parenchyma.
Summary
The literature over the last decade has provided an un-
equivocal mechanistic link between liver angiogenesis and
ﬁbrogenesis. In the complex scenario of a progressive CLD,
several major issues predominate in the relationship be-
tween angiogenesis and ﬁbrogenesis: 1) tissue hypoxia and
cellular responses mediated by HIFs signiﬁcantly modulate
the phenotype as well as migration and functional responses
of all liver cells involved in CLD progression; 2) the in-
teractions (both direct or mediated through the release of
several mediators or signals) between hepatic cells are
critical to both angiogenesis and ﬁbrogenesis, with myoﬁ-
broblasts serving a critical function integrating a variety of
cell-derived signals; and 3) MPs have an important and
increasingly appreciated role in mediating angiogenesis and
vascular remodeling. Future studies are needed to further
unravel the molecular, cell, and tissue mechanisms linking
angiogenesis and ﬁbrogenesis; ultimately, this has the po-
tential to identify new targets for more selective and
effective antiﬁbrotic therapies.References
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